JP2025511145A - Ｘ８４２製剤 - Google Patents

Ｘ８４２製剤 Download PDF

Info

Publication number
JP2025511145A
JP2025511145A JP2024557950A JP2024557950A JP2025511145A JP 2025511145 A JP2025511145 A JP 2025511145A JP 2024557950 A JP2024557950 A JP 2024557950A JP 2024557950 A JP2024557950 A JP 2024557950A JP 2025511145 A JP2025511145 A JP 2025511145A
Authority
JP
Japan
Prior art keywords
solid dispersion
pharmaceutical formulation
carrier
tablet
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511145A5 (enExample
Inventor
ワン，ジャンシン
ヤン，ジャンガン
ホゥ，ピンション
ルゥ，ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Sinorda Biomedicine Co Ltd
Shanghai Sinorda Biomedicine Co Ltd
Original Assignee
Guizhou Sinorda Biomedicine Co Ltd
Shanghai Sinorda Biomedicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Sinorda Biomedicine Co Ltd, Shanghai Sinorda Biomedicine Co Ltd filed Critical Guizhou Sinorda Biomedicine Co Ltd
Publication of JP2025511145A publication Critical patent/JP2025511145A/ja
Publication of JP2025511145A5 publication Critical patent/JP2025511145A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024557950A 2022-03-30 2023-03-23 Ｘ８４２製剤 Pending JP2025511145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2022/084214 WO2023184282A1 (en) 2022-03-30 2022-03-30 X842 formulation
CNPCT/CN2022/084214 2022-03-30
PCT/CN2023/083375 WO2023185624A1 (en) 2022-03-30 2023-03-23 X842 formulation

Publications (2)

Publication Number Publication Date
JP2025511145A true JP2025511145A (ja) 2025-04-15
JP2025511145A5 JP2025511145A5 (enExample) 2026-04-08

Family

ID=81386826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557950A Pending JP2025511145A (ja) 2022-03-30 2023-03-23 Ｘ８４２製剤

Country Status (8)

Country Link
US (1) US20260166014A1 (enExample)
EP (1) EP4499046A1 (enExample)
JP (1) JP2025511145A (enExample)
KR (1) KR20240165457A (enExample)
CN (2) CN119139298A (enExample)
AU (1) AU2023247528A1 (enExample)
MX (1) MX2024011716A (enExample)
WO (2) WO2023184282A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230943A1 (en) * 2023-05-08 2024-11-14 Cinclus Pharma Holding AB (publ) Linaprazan glurate for treating gastroesophageal reflux disease (gerd)
WO2026032974A1 (en) 2024-08-05 2026-02-12 Cinclus Pharma Holding AB (publ) Formulation of linaprazan glurate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368006B1 (en) * 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
CN101513403A (zh) * 2008-02-21 2009-08-26 上海慧德医药科技有限公司 含有苯并咪唑类化合物的药物制剂
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
CN106279151A (zh) * 2015-06-26 2017-01-04 江苏太瑞生诺生物医药科技有限公司 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法
US20210330599A1 (en) * 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2020101860A1 (en) 2018-11-16 2020-05-22 Cnh Industrial America Llc System and method for aligning arms of an agricultural header
EP4054537B1 (en) * 2019-11-04 2023-06-07 Cinclus Pharma Holding AB (publ) Oral formulation of x842
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US20220002297A1 (en) 2020-07-02 2022-01-06 Cinclus Pharma Ag Polymorphs of x842

Also Published As

Publication number Publication date
WO2023184282A1 (en) 2023-10-05
AU2023247528A1 (en) 2024-09-26
US20260166014A1 (en) 2026-06-18
MX2024011716A (es) 2024-11-08
CN119139298A (zh) 2024-12-17
KR20240165457A (ko) 2024-11-22
CN117157059B (zh) 2024-09-13
WO2023185624A1 (en) 2023-10-05
CN117157059A (zh) 2023-12-01
EP4499046A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
JP4780522B2 (ja) フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
CN102316867B (zh) 氨氯地平微球制剂、其制备方法及应用
TW200848056A (en) Solid dispersion of a neurokinin antagonist
WO2023185624A1 (en) X842 formulation
CN111514142B (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
CZ20032647A3 (cs) Pevná farmaceutická kompozice obsahující 4-kyanotrifluor-3-(4-fluorfenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidin a PVP
KR20230155504A (ko) (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를 포함하는 제약 투여 형태
JP2019514993A (ja) 改善された薬物製剤
JP2003534296A (ja) 溶出性の改善されたプランルカスト固体分散系及びその製造方法
KR100209201B1 (ko) 1,4-디히드로피리딘 유도체를 함유하는 고체 분산 정제 및 그의 제조방법
US20160128951A1 (en) Pharmaceutical compositions of fingolimod
US20110274754A1 (en) Oral tablet compositions of dexlansoprazole
US11285152B2 (en) Stable oral pharmaceutical composition of imatinib
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
KR20140050876A (ko) 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
HK40102489B (en) X842 formulation
CN113950324A (zh) 微型软胶囊萘普生组合物
HK40102489A (en) X842 formulation
JP7817367B2 (ja) 難溶性薬物の浸透圧ポンプ制御放出錠剤及びその製造方法
BR112024019689B1 (pt) Formulação farmacêutica para administração oral, dispersão sólida, e, comprimido ou cápsula
JP7058104B2 (ja) アプレピタントを有効成分とする医薬錠剤
CN107249569A (zh) 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂
KR100539706B1 (ko) 타크로리무스 및 장용성 고분자를 함유하는 고체분산체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260319